Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 23, No 6 (February 20), 2005: pp. 1325
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.05.192

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Altundag, K.
Right arrow Articles by Gunduz, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Altundag, K.
Right arrow Articles by Gunduz, M.
Related Articles
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

CORRESPONDENCE

Targeted Therapy for Targeted Patients: Trastuzumab in Adjuvant Treatment of Non–Small-Cell Lung Cancer

Kadri Altundag

Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey

Ozden Altundag

Houston, TX

Paolo Morandi

Department of Medical Oncology, S. Bortolo General Hospital, Vicenza, Italy

Mehmet Gunduz

Department of Otolaryngology, Graduate School of Medicine and Dentistry, Okayama University, Shikata, Japan

To the Editor:

We read with great interest the article by Langer et al1 and editorial by Rosell.2 As they state, identification of subset groups of patients who benefit more from trastuzumab therapy must be the ultimate goal. Studies showed that human papilloma virus (HPV) was detected in the minority of the non–small-cell lung cancer patients.3 Recently published data examined the effect of the cooperation between HPV-16 and the tyrosine kinase receptor HER-2/neu on E-cadherin/catenin complex patterns, which normally prevent metastatic processes in tumor tissue, and reported that coexpression of E6/E7 and ErbB-2 downregulates E-cadherin and catenin expression, resulting in neoplastic transformation of primary normal epithelial cells.4 Kern et al5 stated that patients in early stage with expression of HER-2/neu had inferior survival. In addition to Rosell's proposal for choosing the right patients who benefit more from trastuzumab therapy for lung cancer, we suggest that trastuzumab alone or in combination as an adjuvant treatment in early-stage disease may decrease the relapse rate in patients whose tumor showed HPV-16 E6/E7 positivity and HER-2/neu overexpression.

Authors' Disclosures of Potential Conflicts of Interest

The authors indicated no potential conflicts of interest.

REFERENCES

1. Langer CJ, Stephenson P, Thor A, et al: Trastuzumab in the treatment of advanced non-small-cell lung cancer: Is therea role? Focus on Eastern Cooperative Oncology Group Study 2598. J Clin Oncol 22:1180-1187, 2004[Abstract/Free Full Text]

2. Rosell R: Toward customized trastuzumab in HER-2/neu-overexpressing non-small-cell lung cancers. J Clin Oncol 22:1171-1173, 2004[Free Full Text]

3. Zafer E, Ergun MA, Alver G, et al: Detection and typing of human papillomavirus in non-small cell lung cancer. Respiration 71:88-90, 2004[CrossRef][Medline]

4. Al Moustafa AE, Foulkes WD, Benlimame N, et al: E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells. Oncogene 23:350-358, 2004[Medline]

5. Kern JA, Slebos RJ, Top B, et al: C-erB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93:516-520, 1994


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

  • Trastuzumab in the Treatment of Advanced Non-Small-Cell Lung Cancer: Is There a Role? Focus on Eastern Cooperative Oncology Group Study 2598
    Corey J. Langer, Patricia Stephenson, Ann Thor, Mark Vangel, and David H. Johnson
    JCO 2004 22: 1180-1187 [Abstract] [Full Text]



This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Altundag, K.
Right arrow Articles by Gunduz, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Altundag, K.
Right arrow Articles by Gunduz, M.
Related Articles
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online